Share on LinkedInShare on LinkedIn

ARTICLE · 05 MAY 2025

D. Mass Patent Litigation Update: March 2025

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

This is part of a series of articles discussing recent orders of interest issued in patent cases by the United States District Court for the District of Massachusetts.

United StatesIntellectual Property

This is part of a series of articles discussing recent orders of interest issued in patent cases by the United States District Court for the District of Massachusetts.

In Chr. Hansen HMO GmbH v. Glycosyn LLC, No. 1:22-cv-11090-NMG, Judge Gorton accepted and adopted a Report and Recommendation of Chief Magistrate Judge Cabell and denied Counterclaim-Defendant Abbott Laboratories' motion for summary judgment of failure to join a necessary party in Glycosyn's patent infringement counterclaims against Abbott as Hansen's commercial distributor.

Abbott contended that Glycosyn cannot bring suit by itself because, while Glycosyn owns the asserted counterclaim patents, those patents have been exclusively licensed to Friedland Campina DOMO B.V. ("RFC") in a prior contract ("Agreement"). The Agreement gave RFC the exclusive right to sue for infringement for 120 days after notice of suspected infringement and to grant sublicenses (subject to approval by Glycosyn), after

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from